OCTAGON CAPITAL ADVISORS LP Holdings

OCTAGON CAPITAL ADVISORS LP is an investment fund managing more than 579.43M US dollars. The largest holdings include Apellis Pharmaceuticals, Arcus Biosciences and Chinook Therapeutics. In Q3 2022 the fund bought assets of total value of 151.52M US dollars and sold assets of total value of 44.33M US dollars.

$579.43M

portfolio value

+22.30%

quarter

-42.13%

1 year

OCTAGON CAPITAL ADVISORS LP portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2021	48197000	42561000
Q2 2021	226601000	8601000
Q3 2021	40570000	114232000
Q4 2021	167552000	45573000
Q1 2022	43364000	46453000
Q2 2022	40241000	110473000
Q3 2022	151521000	44331000

OCTAGON CAPITAL ADVISORS LP 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology Apellis Pharmaceuticals, Inc. Portfolio share: 29.50% Portfolio value: 170.95M Avg. open price: $45.95 Current price: $49.41 P/L: +7.51% Sold -3.10% shares Q3 2022	share	29.50%	170.95M	$45.95	$49.41	+7.51%	Sold -3.10% shares Q3 2022
Biotechnology Arcus Biosciences, Inc. Portfolio share: 12.05% Portfolio value: 69.80M Avg. open price: $33.73 Current price: $33.96 P/L: +0.67% Sold -0.06% shares Q3 2022	share	12.05%	69.80M	$33.73	$33.96	+0.67%	Sold -0.06% shares Q3 2022
Biotechnology Chinook Therapeutics, Inc. Portfolio share: 8.66% Portfolio value: 50.16M Avg. open price: $16.27 Current price: $22.77 P/L: +39.97% Bought +88.14% shares Q2 2022	share	8.66%	50.16M	$16.27	$22.77	+39.97%	Bought +88.14% shares Q2 2022
Drug Manufacturers—General Horizon Therapeutics Public Limited Company Portfolio share: 6.67% Portfolio value: 38.65M Avg. open price: $90.92 Current price: $98.48 P/L: +8.31% Bought +89.24% shares Q3 2022	share	6.67%	38.65M	$90.92	$98.48	+8.31%	Bought +89.24% shares Q3 2022
Biotechnology Gossamer Bio, Inc. Portfolio share: 4.23% Portfolio value: 24.50M Avg. open price: $10.67 Current price: $9.29 P/L: -12.92% Sold -25.84% shares Q3 2022	share	4.23%	24.50M	$10.67	$9.29	-12.92%	Sold -25.84% shares Q3 2022
Medical Devices Tandem Diabetes Care, Inc. Portfolio share: 3.92% Portfolio value: 22.72M Avg. open price: N/A Current price: $42.44 P/L: N/A N/A Q3 2022	share	3.92%	22.72M	N/A	$42.44	N/A	N/A Q3 2022
Biotechnology Celldex Therapeutics, Inc. Portfolio share: 3.69% Portfolio value: 21.40M Avg. open price: $33.44 Current price: $36.66 P/L: +9.63% Bought +35.63% shares Q3 2021	share	3.69%	21.40M	$33.44	$36.66	+9.63%	Bought +35.63% shares Q3 2021
SPDR S&P Biotech ETF Portfolio share: 3.33% Portfolio value: 19.30M Avg. open price: $89.88 Current price: $82.88 P/L: -7.79% Bought +336.20% shares Q2 2022	share	3.33%	19.30M	$89.88	$82.88	-7.79%	Bought +336.20% shares Q2 2022
Biotechnology Mirati Therapeutics, Inc. Portfolio share: 2.66% Portfolio value: 15.43M Avg. open price: N/A Current price: $92.75 P/L: N/A N/A Q3 2022	share	2.66%	15.43M	N/A	$92.75	N/A	N/A Q3 2022
Biotechnology Verona Pharma plc Portfolio share: 2.34% Portfolio value: 13.54M Avg. open price: N/A Current price: $13.57 P/L: N/A N/A Q3 2022	share	2.34%	13.54M	N/A	$13.57	N/A	N/A Q3 2022
Biotechnology Vera Therapeutics, Inc. Portfolio share: 1.96% Portfolio value: 11.36M Avg. open price: N/A Current price: $16.19 P/L: N/A Sold -7.26% shares Q3 2022	share	1.96%	11.36M	N/A	$16.19	N/A	Sold -7.26% shares Q3 2022
Biotechnology Harmony Biosciences Holdings, Inc. Portfolio share: 1.86% Portfolio value: 10.78M Avg. open price: N/A Current price: $60.91 P/L: N/A N/A Q3 2022	share	1.86%	10.78M	N/A	$60.91	N/A	N/A Q3 2022
Drug Manufacturers—Specialty & Generic Intra-Cellular Therapies, Inc. Portfolio share: 1.77% Portfolio value: 10.28M Avg. open price: N/A Current price: $54.25 P/L: N/A N/A Q3 2022	share	1.77%	10.28M	N/A	$54.25	N/A	N/A Q3 2022
Biotechnology Stoke Therapeutics, Inc. Portfolio share: 1.69% Portfolio value: 9.80M Avg. open price: $25.36 Current price: $7.16 P/L: -71.77% Sold -6.15% shares Q2 2022	share	1.69%	9.80M	$25.36	$7.16	-71.77%	Sold -6.15% shares Q2 2022
Biotechnology BridgeBio Pharma, Inc. Portfolio share: 1.60% Portfolio value: 9.28M Avg. open price: $39.71 Current price: $9.17 P/L: -76.91% Sold -58.82% shares Q2 2022	share	1.60%	9.28M	$39.71	$9.17	-76.91%	Sold -58.82% shares Q2 2022
Biotechnology Alpine Immune Sciences, Inc. Portfolio share: 1.52% Portfolio value: 8.82M Avg. open price: N/A Current price: $6.78 P/L: N/A N/A Q3 2022	share	1.52%	8.82M	N/A	$6.78	N/A	N/A Q3 2022
Biotechnology Ascendis Pharma A/S Portfolio share: 1.49% Portfolio value: 8.62M Avg. open price: N/A Current price: $119.41 P/L: N/A N/A Q3 2022	share	1.49%	8.62M	N/A	$119.41	N/A	N/A Q3 2022
Biotechnology Karuna Therapeutics, Inc. Portfolio share: 1.34% Portfolio value: 7.76M Avg. open price: N/A Current price: $226.95 P/L: N/A N/A Q3 2022	share	1.34%	7.76M	N/A	$226.95	N/A	N/A Q3 2022
Biotechnology Alnylam Pharmaceuticals, Inc. Portfolio share: 1.29% Portfolio value: 7.46M Avg. open price: N/A Current price: $226.4 P/L: N/A N/A Q3 2022	share	1.29%	7.46M	N/A	$226.4	N/A	N/A Q3 2022
Biotechnology Fate Therapeutics, Inc. Portfolio share: 1.28% Portfolio value: 7.42M Avg. open price: N/A Current price: $20.4 P/L: N/A N/A Q3 2022	share	1.28%	7.42M	N/A	$20.4	N/A	N/A Q3 2022
Biotechnology Xilio Therapeutics, Inc. Portfolio share: 1.22% Portfolio value: 7.05M Avg. open price: N/A Current price: $2.43 P/L: N/A N/A Q3 2022	share	1.22%	7.05M	N/A	$2.43	N/A	N/A Q3 2022
Biotechnology Avidity Biosciences, Inc. Portfolio share: 1.07% Portfolio value: 6.19M Avg. open price: $16.98 Current price: $11.18 P/L: -34.14% Bought +18.03% shares Q3 2022	share	1.07%	6.19M	$16.98	$11.18	-34.14%	Bought +18.03% shares Q3 2022
Biotechnology 4D Molecular Therapeutics, Inc. Portfolio share: 0.69% Portfolio value: 4.02M Avg. open price: $33.16 Current price: $23.17 P/L: -30.13% Sold -20.98% shares Q3 2022	share	0.69%	4.02M	$33.16	$23.17	-30.13%	Sold -20.98% shares Q3 2022
Biotechnology Nuvalent, Inc. Portfolio share: 0.67% Portfolio value: 3.88M Avg. open price: N/A Current price: $34.16 P/L: N/A N/A Q3 2022	share	0.67%	3.88M	N/A	$34.16	N/A	N/A Q3 2022
Biotechnology Jounce Therapeutics, Inc. Portfolio share: 0.57% Portfolio value: 3.27M Avg. open price: N/A Current price: $0.91 P/L: N/A N/A Q3 2022	share	0.57%	3.27M	N/A	$0.91	N/A	N/A Q3 2022
Biotechnology Immunovant, Inc. Portfolio share: 0.56% Portfolio value: 3.23M Avg. open price: $8.36 Current price: $14.36 P/L: +71.77% Sold -60.74% shares Q2 2022	share	0.56%	3.23M	$8.36	$14.36	+71.77%	Sold -60.74% shares Q2 2022
Medical Devices DexCom, Inc. Portfolio share: 0.56% Portfolio value: 3.22M Avg. open price: N/A Current price: $116.56 P/L: N/A N/A Q3 2022	share	0.56%	3.22M	N/A	$116.56	N/A	N/A Q3 2022
Biotechnology Akero Therapeutics, Inc. Portfolio share: 0.44% Portfolio value: 2.55M Avg. open price: N/A Current price: $44.04 P/L: N/A N/A Q3 2022	share	0.44%	2.55M	N/A	$44.04	N/A	N/A Q3 2022
Biotechnology Century Therapeutics, Inc. Portfolio share: 0.38% Portfolio value: 2.21M Avg. open price: $27.94 Current price: $10.25 P/L: -63.32% Sold -13.73% shares Q3 2022	share	0.38%	2.21M	$27.94	$10.25	-63.32%	Sold -13.73% shares Q3 2022
Biotechnology Mirum Pharmaceuticals, Inc. Portfolio share: 0.36% Portfolio value: 2.10M Avg. open price: N/A Current price: $18.33 P/L: N/A N/A Q3 2022	share	0.36%	2.10M	N/A	$18.33	N/A	N/A Q3 2022
Biotechnology BeiGene, Ltd. Portfolio share: 0.26% Portfolio value: 1.52M Avg. open price: N/A Current price: $188.71 P/L: N/A N/A Q3 2022	share	0.26%	1.52M	N/A	$188.71	N/A	N/A Q3 2022
Biotechnology Mereo BioPharma Group plc Portfolio share: 0.15% Portfolio value: 861K Avg. open price: N/A Current price: $0.83 P/L: N/A N/A Q2 2022	share	0.15%	861K	N/A	$0.83	N/A	N/A Q2 2022
Biotechnology Connect Biopharma Holdings Limited Portfolio share: 0.10% Portfolio value: 581K Avg. open price: N/A Current price: $0.71 P/L: N/A N/A Q3 2022	share	0.10%	581K	N/A	$0.71	N/A	N/A Q3 2022
Biotechnology Bicycle Therapeutics plc Portfolio share: 0.08% Portfolio value: 465K Avg. open price: N/A Current price: $32.41 P/L: N/A N/A Q3 2022	share	0.08%	465K	N/A	$32.41	N/A	N/A Q3 2022
Biotechnology ADC Therapeutics SA Portfolio share: 0.03% Portfolio value: 145K Avg. open price: N/A Current price: $3.52 P/L: N/A N/A Q3 2022	share	0.03%	145K	N/A	$3.52	N/A	N/A Q3 2022
Biotechnology Arvinas, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $82.18 Current price: $39.53 P/L: -51.90% Sold -100.00% shares Q3 2022	share	0.00%	0	$82.18	$39.53	-51.90%	Sold -100.00% shares Q3 2022
Biotechnology Ambrx Biopharma Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $0.52 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$0.52	N/A	Sold -100.00% shares Q3 2022
Biotechnology Keros Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $50 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$50	N/A	Sold -100.00% shares Q3 2022
Biotechnology Prometheus Biosciences, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $37.72 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$37.72	N/A	Sold -100.00% shares Q3 2022
Biotechnology I-Mab Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $57.19 Current price: $3.71 P/L: -93.51% Sold -100.00% shares Q3 2022	share	0.00%	0	$57.19	$3.71	-93.51%	Sold -100.00% shares Q3 2022

Showing TOP 40 OCTAGON CAPITAL ADVISORS LP's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of OCTAGON CAPITAL ADVISORS LP?

The biggest position of the OCTAGON CAPITAL ADVISORS LP is Apellis Pharmaceuticals, Inc. (APLS) with 29.5% portfolio share worth of 170.96M US dollars.

Top 5 OCTAGON CAPITAL ADVISORS LP's holdings represent 61.11% of the portfolio:

Apellis Pharmaceuticals, Inc. (APLS) – 29.5%
Arcus Biosciences, Inc. (RCUS) – 12.05%
Chinook Therapeutics, Inc. (KDNY) – 8.66%
Horizon Therapeutics Public Limited Company (HZNP) – 6.67%
Gossamer Bio, Inc. (GOSS) – 4.23%

Who is the portfolio manager of OCTAGON CAPITAL ADVISORS LP?

The portfolio manager of the OCTAGON CAPITAL ADVISORS LP is .

What is the total asset value of the OCTAGON CAPITAL ADVISORS LP portfolio?

OCTAGON CAPITAL ADVISORS LP total asset value (portfolio value) is 579.43M US dollars.

Who is ?

is the portfolio manager of the OCTAGON CAPITAL ADVISORS LP.

What is (OCTAGON CAPITAL ADVISORS LP) fund performance?

OCTAGON CAPITAL ADVISORS LP's quarterly performance is +22.30%, annualy -42.13%.

What is the OCTAGON CAPITAL ADVISORS LP CIK?

OCTAGON CAPITAL ADVISORS LP's Central Index Key is 0001839435 .